Alberta Participant Webinar: Update on the Canadian Longitudinal Study on Aging (CLSA)



Land Acknowledgement

The University of Calgary, located in the heart of Southern Alberta, both acknowledges and pays tribute to the traditional territories of the people of Treaty 7, which includes the Blackfoot Confederacy (comprising the Siksika, the Piikani, the Kainai First Nations), the Stoney Nakoda (including Chiniki, Bearspaw, and Wesley First Nations) and Tsuut'ina First Nation. The City of Calgary is also home to Region III of the Métis Nation of Alberta. By virtue of the signing of Treaty 7 in 1877, the University recognizes that we are all treaty people.

Objectives/ Timeline

- Provide an update on the CLSA (~20 minutes)
 - Site: Berchman Wong
 - Study: Dr. David Hogan
- Review COVID-19 related studies being done (~20 minutes)
 - Dr. Jacqueline McMillan
- Answer questions submitted prior to the webinar (~20 minutes)
 - Drs. Hogan & McMillan

2020-2021 CLSA Site Highlights

- Adapting to COVID-19 pandemic
- Successfully supporting the CLSA COVID study
- Successfully supporting the CLSA COVID Antibody study
- Balancing CLSA and local U of C requirements for the conduct of research
- Keeping everyone healthy and well

Calgary Team:

IH: Pam, Glenn, Amy, Mark

DCS: Lorlene, Jessica, Kim, Steve

Lab: Loan

Coordinator: Berchman

PI: Dr. Hogan, Dr. McMillan





Canadian Longitudinal Study on Aging (CLSA) as a Platform for Research on Healthy Aging

Dr. David B. Hogan
University of Calgary

on behalf of the CLSA Research Team

Tuesday, June 22, 2021



Canadian Longitudinal Study on Aging Étude longitudinale canadienne sur le vieillissement

CLSA National Leads



Christina Wolfson
Principal Investigator
McGill University



Parminder Raina
Lead Principal
Investigator
McMaster University



Susan Kirkland Principal Investigator Dalhousie University

What is the CLSA?

A research platform –
Infrastructure to enable
state-of-the-art, interdisciplinary
population-based research
and evidenced-based
decision-making that will lead
to better health and quality of
life for Canadians.



Key Points about the CLSA

 Major strategic initiative of CIHR; on Canadian research agenda since 2001

 More than 160 researchers and collaborators – 26 institutions

 Multidisciplinary – biology, genetics, medicine, psychology, sociology, demography, economics, epidemiology, nutrition, health services

 Largest research platform of its kind in Canada for breadth & depth

 Following 50,000+ Canadians aged 45-85 at baseline for 20 years



CLSA Network of Collaborating Institutions



























a place of mind
THE UNIVERSITY OF BRITISH COLUMBIA





University of Victoria



UNIVERSITÉ DE SHERBROOKE



Canadian Longitudinal Study on Aging Étude longitudinale canadienne sur le vieillissement

Participants

Tracking Cohort

- Target 20,000 participants from all 10 provinces, followed through Computer-Assisted Telephone Interviews (~1 hour at baseline)
- 21,241 recruited

Comprehensive Cohort

- Target 30,000 participants living within 25 km (or 50 km) of a CLSA Data Collection Site (DCS)
- Followed through in-home interviews (~1 hour) and further assessments (~2-3 hours) at a DCS
- 30,097 recruited



CLSA Infrastructure

Computer-Assisted Telephone Interview

(CATI) Centres

















CLSA Data Collection

Data Collection Sites

Interviews/ Physical Assessments

- Height, Weight, BMI
- Bone Density, Body
 Composition, Aortic Calcification
- Blood Pressure
- ECG
- Carotid Intima-Media Thickness
- Pulmonary Function
- Vision & HearingPerformance testing

Biospecimen Collection

- Blood
- Urine

Cognitive Assessments

- Memory
- Executive function
- Reaction time

CLSA Research Platform

50,000 participants aged 45 - 85 at baseline

Target: 20,000

Actual: 21,241


Randomly selected within

provinces


Target: 30,000 Actual: 30,097

Randomly selected

within 25-50 km of 11 sites



National Scope



Withdrawal Rate

- By the end of the first follow-up, 4.3% of participants had withdrawn from active data collection though most (60.8%) of those withdrawn consented to continue passive data collection through data linkage
 - An additional 2.7% of participants had died since their baseline assessment
- Accommodations made to keep in the study
 - This includes those who move from one area to another or to LTC, modify data collection (e.g., "DCS at home" if can't come), appoint a proxy to answer for them

How the collected data are being used

- Approved projects 72 in 2020 alone
 - www.clsa-elcv.ca/approved-projects
- 150 publications
 - www.clsa-elcv.ca/stay-informed/publications
- Literature
 - "Aging in Three-Year Increments" by Laura Wershler (in You Look Good for Your Age: An Anthology; edited by Rona Altrows [University of Alberta Press, May 2021])

2018 Report on Baseline Data (2010-2015)

- Highlights (Alberta participants 4,964)
 - 90% rated health as good/very good/ excellent
 - 95% rated mental health as good/very good/excellent – 45-54 had the most concerns
 - More women than men reported loneliness
 - 1/20 had suffered a fall in last year
 - 25% were as physically active as recommended
- Download <u>www.clsa-elcv.ca/clsareport</u>

Highlights of 2020-2021

- Responding to the COVID-19 pandemic (to come)
- A further investment by the Canada Foundation for Innovation (CFI) in the CLSA to renew our infrastructure & add new tools to identify the causes & early stages of chronic health conditions such as mobility impairment, disability & cognitive decline
- Additional funding to address dementia
- Hosted the CIHR-IA 2021 Summer Program on Aging
- Funding provided by CIHR to use CLSA data







Contact:

Data inquiries: access@clsa-elcv.ca General inquiries: info@clsa-elcv.ca

CLSA is funded by the Government of Canada through CIHR and CFI, and provincial governments and universities

www.clsa-elcv.ca



Responding to COVID-19

Dr. Jacqueline McMillan

- March 2020: In-person data collection suspended
- Migration to telephone interviews
- Development of COVID-19 questionnaires







CLSA COVID-19 Questionnaire Study

- Launched April 2020
- Web and telephone questionnaires
- Weekly, biweekly, monthly data collection
- 28,000 baseline participants
- Exit survey fall 2020
- Funded through the McMaster Institute for Research on Aging, McMaster University, Juravinski Research Institute, the Nova Scotia COVID-19 Health Research Coalition and the Public Health Agency of Canada




CLSA COVID-19 Questionnaire Study

- COVID symptoms
- COVID status
- Risk factors
- Health-care use
- Health behaviours

- Public Health measures
- Social factors
- Depression and anxiety
- Economic consequences
- Function and mobility




CLSA COVID-19 Study Recruitment






Étude longitudinale canadienne sur le vieillissement

CLSA COVID-19 Questionnaire Study



COVID-19 Study Data Dashboard








COVID-19 Antibody Study Questionnaire Study

- Learnings to date:
 - Vaccination willingness
 - Mental health
 - Mobility and function
 - Long-haul covid





 To understand prevalence and impact of SARS-CoV-2 infection among middle-aged and older adults in Canada







- Launched November 2020
- 19,000 CLSA participants
- Blood sample to determine if a person has been previously infected with SARS-CoV-2 or vaccinated against SARS-CoV-2
- 3 waves of data collection
- \$4M investment from the Government of Canada's COVID-19 Immunity Task Force (CITF)





COVID-19 Antibody Study Venous Blood Collection

- Venous blood collection at CLSA Data Collection Sites
- Enhanced health and safety measures, COVID-19 screening
- 50 mL of blood (about 3 tbsp)
- Telephone questionnaire
- Partners: Alberta Precision Laboratories (APL), FedEx, CITF







COVID-19 Antibody Study Dried Blood Spot

- Self-collection at home
- 4-5 drops of blood from fingertip using blood collection kit
- Telephone or online questionnaire
- Partners: Boston Microfluidics, APL, FedEx, CITF







- Seroprevalence = the level of pathogen in a population, as measured in blood serum
 - Pathogen- SARS-CoV-2
 - Population- a subset of CLSA participants
 - Serum- component of blood





- Pathogen- SARS-CoV-2 (cause of COVID-19)
 - Tests detect antibodies to SARS-CoV-2
 - Antibodies are protective proteins produced by the immune system
 - Antibodies indicate an immune response to a foreign body
 - We tested for 2 common antibodies to SARS-CoV-2





- Participants will receive a letter with their results
- The letter will indicate the results of each test
- Nucleocapsid +/-
- Spike protein +/-
- Antibodies can be produced to both after infection
- Current vaccines in Canada use spike protein
- An interpretation of the results will be provided
- A frequently asked questions sheet will be provided





- Seroprevalence (presence of antibodies) = the level of pathogen in a population, as measured in blood serum
 - Pathogen- SARS-CoV-2
 - Population- a subset of CLSA participants
- We should not change individual-level behavior based on results of a population-level study
- Continue to adhere to public health measures to prevent infection and transmission





- Negative results can occur:
 - In blood collected too soon after infection or vaccination
 - In persons who are immunosuppressed
 - In persons with mild or asymptomatic infection
 - If concentrations are below the detection limit of the test
 - Results should not be used to diagnose recent infection

Additional information about serology tests and results

- www.canada.ca/en/health-canada/services/drugs-healthproducts/covid19-industry/medicaldevices/testing/serological/information-for-patients.html
- www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibodytests-guidelines.html
- www.fda.gov/medical-devices/safety-communications/antibodytesting-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety



CLSA COVID-19 Brain Health

- Canadian Institutes of Health Research
- Weston Brain Institute
- Teresa Liu-Ambrose, University of British Columbia
- Eric E Smith, University of Calgary
- Parminder Raina, McMaster University






CLSA COVID-19 Brain Health

- To explore the impact of the COVID-19 pandemic on human cognition and brain health.
- Our current understanding is limited to acute and overt manifestations.
- We focus on understanding the possible covert neurological consequences of COVID-19 and their impact on human brain and cognition.



CLSA Research Platform



2015-2018 Follow-up 1

2018-2021 Follow-up 2

2021-2024 Follow-up 3





COVID-19

Questionnaire Study

- Launched April 2020
- Web and telephone surveys
- Weekly, biweekly, monthly
- 28,000 baseline participants



COVID-19 Antibody Study

- Launched November 2020
- Recruiting 19,000 CLSA participants
- Dried blood spots samples (self-collection)
- Venous blood sample collection at CLSA Data Collection Sites



Health Study

Impact of COVID-19 on cognition & brain health

Thank you!

Questions?